Adjuvant treatment of breast cancer in 2004. A review of the 8th consensus conference of St. Gallen and new study results;Adjuvante therapie des mammakarzinoms 2004 eine bewertung der 8. Konsensuskonferenz von St. Gallen und neuer studienergebnisse

Gynakologisch-geburtshilfliche Rundschau

Volumn 44, Issue 2, 2004, Pages 102-112

  Kahlert, S ^a   Von Koch, F ^a   Ditsch, N ^a   Untch, M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adjuvant therapy; Anthracyclines; Aromatase inhibitors; Dose dense therapy; Early breast cancer; Taxanes

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; LETROZOLE; TAMOXIFEN; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DECISION MAKING; DRUG HYPERSENSITIVITY; DRUG POTENCY; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; POSTMENOPAUSE; RANDOMIZATION; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CRITICAL PATHWAYS; FEMALE; HUMANS; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 1842686091     PISSN: 10188843     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076863     Document Type: Review

References (29)

1. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001;19:3817-3827.
2. Goldhirsch A, Wood WC, Gelber RD, et al: Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-3365.
3. Fisher B, Anderson S, Tan-Chiu E, et al: Tamoxifen and chemotherapy for axillary nodenegative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931-942.
4. Albain KS, Green SJ, Ravdin PM, et al: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from Intergroup trial 0100 (SWOG-8814) (Abstract 143). Proc Am Soc Clin Oncol 2002;21:37a.
5. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483-1496.
6. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:2651-2658.
7. Hutchins L, Green SJ, Ravdin PM, et al: CMF and CAF with and without tamoxifen in highrisk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of Intergroup trial INT 0102 (abstract 2). Proc Am Soc Clin Oncol 1998;17:1a.
8. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
9. Bergh J, Wiklund T, Erikstein B, et al: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000;356:1384-1391.
10. Nabholtz J-M, Pienkowski T, Mackey J, et al: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study (Abstract 141). Proc Am Soc Clin Oncol 2002;21:36a.
11. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359:2131-2139.
12. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-1810.
13. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
14. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-690.
15. Boccardo F, Rubagotti A, Amoroso D, et al: Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment (Abstract 3). Breast Cancer Res Treat 2003;82(suppl 1):S6-S7.
16. EBCTCG: Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-942.
17. Pritchard KI, O'Malley FA, Andrulis I, et al: Prognostic and predictive value of Her2/neu in a randomized trial comparing CMF to CEF in premenopausal women with axillary lymph node positive breast cancer (NCIC CTG MA.5) (Abstract 165). Proc Am Soc Clin Oncol 2002;21:42a.
18. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
19. FASG: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19:602-611.
20. Fumoleau P, Kerbrat P, Romestaing P, et al: Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003;21:298-305.
21. Piccart MJ, Di Leo A, Beauduin M, et al: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001;19:3103-3110.
22. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003;21:843-850.
23. Mamounas EP, Bryant J, Lembersky BC, et al: Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28 (Abstract 12). Proc Am Soc Clin Oncol 2003;22:4a.
24. Hutcheon AW, Heys SD, Sarkar TK: Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat 2003;79(suppl 1):S19-S24.
25. Trudeau ME: Optimizing adjuvant breast cancer chemotherapy: Rationale for the MA.21 study. Oncology (Huntingt) 2001;15(suppl 7):7-13.
26. Rack B, Janni W, Harbeck N, et al: Phase III study evaluating the role of docetaxel in the adjuvant therapy of breast cancer patients with extensive lymph node involvement (4 nodes+) - ADEBAR study. Breast 2003;12(suppl 1):S37.
27. Norton L: A Gompertzian model of human breast cancer growth. Cancer Res 1988;48(24, Pt 1):7067-7071.
28. Untch M, Thomssen C, Kahlert S, et al: Five year results of a randomised multicenter dose intense (DI-EC) study with epirubicin (E) and cyclophosphamide (C) in high risk breast cancer patients - A treatment of short duration with comparable efficacy to conventional chemotherapy (Abstract 641). Breast Cancer Res Treat 2002;76(suppl 1):S158.
29. Venturini M, Aitini E, Del Mastro L, et al: Phase III adjuvant trial comparing standard versus accelerated FEC regimen in early breast cancer patients: Results from GONO-MIG1 study. Breast Cancer Res Treat 2003;82(suppl 1):S9.